A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04259281 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 6, 2020
Last Update Posted : April 2, 2024
|
Sponsor:
Ultragenyx Pharmaceutical Inc
Information provided by (Responsible Party):
Ultragenyx Pharmaceutical Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT) injection to participants with Angelman Syndrome (AS).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Angelman Syndrome | Drug: GTX-102 | Phase 1 Phase 2 |
This is a Phase 1/2, open-label, multiple-dose, study to evaluate the safety, tolerability, and plasma and CSF concentrations of GTX-102 in pediatric participants with AS.
The study includes a Loading phase followed by a Maintenance phase. Participants may continue on GTX-102 during the Maintenance phase of the study until GTX-102 is commercially available, intolerable toxicity occurs, the parent/legal guardian withdraws consent, the participant enrolls in another experimental study, or this study is terminated.
This study was previously posted by GeneTX Biotherapeutics, LLC and was transferred to Ultragenyx in July 2022.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 74 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS) |
| Actual Study Start Date : | February 24, 2020 |
| Estimated Primary Completion Date : | December 2025 |
| Estimated Study Completion Date : | December 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Angelman syndrome
| Arm | Intervention/treatment |
|---|---|
|
Experimental: GTX-102 Cohort 1
3.3 mg starting dose followed by intra-patient dose escalation up to 36 mg and then a maintenance phase (in U.S participants 4 to <17 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Cohort 2
10 mg starting dose followed by intra-patient dose escalation up to 36 mg and then a maintenance phase (in U.S participants 4 to <17 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Cohort 3
20 mg starting dose followed by intra-patient dose escalation up to 55 mg and then a maintenance phase (in U.S participants 4 to <17 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Cohort 4
3.3 mg starting dose followed by slow intra-patient dose escalation up to 5 mg and then a maintenance phase (in Ex-U.S participants 4 to <8 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Cohort 5
5 mg starting dose followed by slow intra-patient dose escalation up to 7.5 mg and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Cohort 6
7.5 mg starting dose followed by slow intra-patient dose escalation up to 10 mg and then a maintenance phase (in Ex-U.S participants 4 to <8 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Cohort 7
10 mg starting dose followed by slow intra-patient dose escalation up to 12 mg and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Cohort US
2 mg for 4 monthly doses followed by a quarterly maintenance regimen
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Expanded Enrollment Cohort A
Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in Ex-U.S participants 4 to <8 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Expanded Enrollment Cohort B
Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Expanded Enrollment Cohort C
Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in U.S participants 4 to <8 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Expanded Enrollment Cohort D
Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in U.S participants ≥ 8 to 17 years of age)
|
Drug: GTX-102
antisense oligonucleotide |
|
Experimental: GTX-102 Cohort E
Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in participants that transition from GTX-102 US Cohort only)
|
Drug: GTX-102
antisense oligonucleotide |
Primary Outcome Measures :
- Number of Participants with Adverse Events (AEs), Serious AEs (SAEs), Adverse Events of Special Interest (AESIs), AEs Leading to Discontinuation and Severity of AEs [ Time Frame: Up to Day 337 ]
Secondary Outcome Measures :
- Pharmacokinetics of GTX-102 over time [ Time Frame: Up to Day 337 ]Maximum drug concentration (Cmax)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed informed consent from parent(s) or legal guardian(s)
- Documented genetic confirmation of full maternal UBE3A gene deletion causing AS in the region of 15q11.2-q13 including class I, II or III
- Stable seizure control (defined as clinically stable with no changes in antiepileptic medications over the prior 1 month before the screening visit, other than weight associated dose adjustments)
- Able to ambulate independently, or with an assistive device (note, a child whose primary means of mobility is by wheelchair is excluded from the study)
- Platelet count, prothrombin time / international normalized ratio, and partial thromboplastin time within 1.2 x the normal limits
- Normal renal function with serum creatinine and spot urine protein ≤ 1.4 x the upper limit of normal (ULN)
- Normal hepatic function with total bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase ≤ 1.4 x ULN. Exception: levels ≤ 2 × ULN are acceptable if due to anti-epileptic drugs (AEDs) or Gilbert syndrome
- Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, study restrictions, and all study procedures, including LP procedure
- Able to tolerate the anesthetic regimen, if required for LP procedure
- A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Female of non-childbearing potential (ie, pre-menarche), Female of childbearing potential who agrees to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for at least 3 months after the final dose of GTX-102
- A male patient is eligible to participate if he agrees to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for at least 3 months after the final dose of GTX-102
Exclusion Criteria:
- Any change in medications (excluding AEDs) or diet/supplements intended to treat symptoms of AS (eg, sleeping aids, supplements, dietary change including ketogenic or low-glycemic index diet, other) over the prior 1 month before screening
- Any bleeding or platelet disorder
- Any clinically significant cardiovascular, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurological, malignant, metabolic, psychiatric, or other condition that, in the judgment of the Investigator, will pose a safety risk, make the patient unsuitable for participation in, and/or unable to complete the study procedures
- Any laboratory abnormality, that, in the Investigator's opinion, could adversely affect the safety of the patient, make it unlikely that the course of treatment or follow up would be completed, or impair the assessment of study result
- Known positive for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus
- Any active infection
- Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
- Drugs that increase the risk of bleeding (eg, heparin, low molecular weight heparin, platelet inhibitors)
- Any prior use of gene therapy
- Use of any investigational drugs in the past 6 months or within 5 half-lives, whichever period is greater (with the exception of prior GTX 102)
- Known hypersensitivity to any oligonucleotide, as demonstrated by an immune mediated reaction (eg, pneumonitis, hepatitis, nephritis, neuritis, or other system inflammation), or a systemic allergic reaction such as signs and symptoms of anaphylaxis, urticaria, clinically significant rash
- Patient is pregnant or lactating
- Any medical condition that would require intubation for the anesthesia procedure
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04259281
Locations
Show 25 study locations
Sponsors and Collaborators
Ultragenyx Pharmaceutical Inc
Investigators
| Study Director: | Medical Director | Ultragenyx Pharmaceutical Inc |
| Responsible Party: | Ultragenyx Pharmaceutical Inc |
| ClinicalTrials.gov Identifier: | NCT04259281 |
| Other Study ID Numbers: |
GTX-102-001 2021-001793-36 ( EudraCT Number ) |
| First Posted: | February 6, 2020 Key Record Dates |
| Last Update Posted: | April 2, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Angelman Syndrome Syndrome Disease Pathologic Processes Movement Disorders Central Nervous System Diseases |
Nervous System Diseases Abnormalities, Multiple Congenital Abnormalities Chromosome Disorders Genetic Diseases, Inborn Imprinting Disorders |